BTAIQ on OTC
BioXcel Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Polomar Health Services, Inc., NovaBridge Biosciences or Karuna Therapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$164.0K
- Research and development59¢$30.3M
- Selling, general and admin40¢$20.5M
Out of $642.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Product revenue, net | $642.0K | $2.3M |
| Cost of goods sold | $164.0K | $2.1M |
| Research and development | $30.3M | $30.4M |
| Selling, general and administrative | $20.5M | $34.5M |
| Restructuring costs | $194.0K | $2.4M |
| Total operating expenses | $51.1M | $69.5M |
| Loss from operations | -$50.5M | -$67.2M |
| Interest expense | $17.0M | $15.1M |
| Interest income | -$1.1M | -$2.6M |
| Other (income) expense, net | $3.5M | -$20.2M |
| Net loss | -$69.9M | -$59.6M |
| Basic net loss per share attributable to common stockholders (in dollars per share) | -$5.73 | -$23.51 |
| Diluted net loss per share attributable to common stockholders (in dollars per share) | -$5.73 | -$23.51 |
| Weighted average shares outstanding - basic (in shares) | 12.2M shares | 2.5M shares |
| Weighted average shares outstanding - diluted (in shares) | 12.2M shares | 2.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $28.4M | $29.9M | |
| Restricted cash | $342.0K | $0 | |
| Accounts receivable, net | $233.0K | $131.0K | |
| Inventory | $722.0K | $679.0K | |
| Prepaid expenses | $4.0M | $5.3M | |
| Other current assets | $10.9M | $1.4M | |
| Total current assets | $44.7M | $37.4M | |
| Property and equipment, net | $175.0K | $475.0K | |
| Operating lease right-of-use assets | $56.0K | $382.0K | |
| Other assets | $0 | $87.0K | |
| Total assets | $44.9M | $38.3M | |
| Accounts payable | $14.7M | $16.0M | |
| Accrued expenses | $4.3M | $5.8M | |
| Current portion of long-term debt | $24.9M | $0 | |
| Total current liabilities | $53.9M | $22.2M | |
| Long-term portion of operating lease liabilities | $0 | $65.0K | |
| Derivative liabilities | $1.8M | $6.6M | |
| Long-term debt | $84.7M | $102.5M | |
| Total liabilities | $140.4M | $131.4M | |
| Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.001 par value, 200,000 shares authorized as of December 31, 2025 and December 31, 2024; 22,328 and 3,102 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $76.0K | $49.0K | |
| Additional paid-in-capital | $624.6M | $557.0M | |
| Accumulated deficit | -$720.1M | -$650.2M | |
| Total stockholders' (deficit) equity | -$95.5M | -$93.1M | -$56.5M |
| Total liabilities and stockholders' (deficit) equity | $44.9M | $38.3M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 22.3M shares | 3.1M shares | |
| Common stock, shares outstanding (in shares) | 22.3M shares | 3.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$69.9M | -$59.6M |
| Depreciation | $300.0K | $309.0K |
| Accretion of debt discount and amortization of financing costs | $1.7M | $467.0K |
| Change in fair value of derivative liabilities | $3.5M | -$20.2M |
| Stock-based compensation expense | $2.8M | $6.2M |
| Payable-in-kind interest on Credit Agreement | $5.4M | $6.5M |
| Operating lease right-of-use assets | $326.0K | $306.0K |
| Accounts receivable | -$102.0K | -$60.0K |
| Inventory | -$43.0K | $1.3M |
| Prepaid expenses, other current assets and other assets | -$8.2M | -$1.9M |
| Accounts payable, accrued expenses, due to related parties, and other current liabilities | $7.0M | -$4.3M |
| Accrued interest | $0 | -$736.0K |
| Operating lease liabilities | -$374.0K | -$346.0K |
| Net cash used in operating activities | -$57.6M | -$72.0M |
| Purchases of equipment and leasehold improvements | $0 | $0 |
| Net cash from investing activities | $0 | $0 |
| Proceeds from issuance of common stock and warrants | $58.1M | $39.7M |
| Payment of principal of Long-term debt | $0 | -$2.5M |
| Offering costs for common stock and warrants issuance | -$1.6M | -$474.0K |
| Payment of employee tax obligations related to vesting restricted stock units | -$17.0K | -$54.0K |
| Net cash provided by financing activities | $56.5M | $36.7M |
| Net decrease in cash, cash equivalents and restricted cash | -$1.1M | -$35.4M |
| Issuance of stock purchase warrants | $0 | $2.5M |
| Repricing of stock purchase warrants | $0 | $59.0K |
| Interest paid | $9.7M | $8.0M |
| Litigation settlement liability and related other current assets | $9.8M | $0 |
Recent filings
- Sep 1, 20268-K
- Aug 28, 20268-K
- Aug 25, 20268-K
- Aug 24, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 20263 OWNERSHIP DOCUMENT
- Aug 14, 20264 OWNERSHIP DOCUMENT
- Aug 13, 202610-Q
- Aug 11, 20268-K
- Aug 3, 20268-K
- Jul 6, 20268-K
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10